Sarcomas/TGCT | Specialty

Dr. Gorlick on the Use of Integrative Surfaceome Profiling to Identify Targets in Osteosarcomas

April 12th 2021

Richard Gorlick, MD, discussed results from a study examining the use of integrative surfaceome profiling to identify immunotherapeutic targets in patients with osteosarcomas.

Dr. Trent on the Role of Avapritinib in PDGFRA Exon 18+ GIST

April 9th 2021

Jonathan C. Trent, MD, PhD, discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor.

Dr. Murphy on Remaining Questions With SBRT in Pediatric Sarcoma

April 8th 2021

Erin Murphy, MD, discusses remaining questions with stereotactic body radiotherapy in pediatric sarcoma.

Clinical Benefit of Ripretinib Expands as Investigators Consider Future Directions

April 8th 2021

Encouraging efficacy data for ripretinib as a later-line therapy for patients with advanced gastrointestinal stromal tumor have investigators hypothesizing new approaches to derive even greater benefit with the agent.

Dr. Murphy on the Clinical Implications of Pazopanib Plus SBRT in Pediatric Sarcoma

April 7th 2021

Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.

Dr. Murphy on Future Research Efforts With Pazopanib Plus SBRT in Pediatric Sarcoma

April 6th 2021

Erin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.

Dr. Wagner on the Rationale for Immunotherapy in Angiosarcoma

April 5th 2021

Michael Wagner, MD, discusses the rationale for using immunotherapy in the treatment of patients with angiosarcoma.

FDA Grants Fast Track Status to Annamycin for Soft Tissue Sarcoma Lung Metastases

March 30th 2021

The FDA has granted a fast track designation for annamycin as a treatment for patients with soft tissue sarcoma lung metastases.

Dr. Trent on the Utility of ctDNA to Understand Primary Mutations in GIST

March 19th 2021

Jonathan C. Trent, MD, PhD, discusses the utility of circulating tumor DNA to understand primary driver mutations in gastrointestinal stromal tumor.

Extremity Sarcoma Trial Utilizes Patient Willingness Outcomes to Gauge Accrual

March 19th 2021

Most patients with extremity sarcoma are willing to participate in a randomized clinical trial exploring various postoperative cancer surveillance regimens.

x